Menopause study finds an abrupt shift across several body systems
A peer-reviewed Nature Medicine analysis realigned laboratory records around the final menstrual period and reported abrupt changes in endocrine, skeletal, liver, kidney and lipid measures across two large datasets. The pattern does not mean every woman experiences the same changes at the same moment; independent Australian experts urged caution about that interpretation. The study sharpens questions about the timing of menopause-related changes without itself prescribing individual diagnosis or treatment.
Science··Evening
A sharp transition appears in laboratory records
A peer-reviewed observational paper published in Nature Medicine on 12 October analysed more than 300 million laboratory tests from two datasets in the United States and Israel. Because the age at the final menstrual period was not recorded for each woman, the researchers reconstructed a shared timeline around that event. At the population level they reported step-like changes in endocrine, bone, liver, kidney and blood-lipid measures.[1], [2]
The final menstrual period is the biological marker used to define menopause retrospectively. The method aims to recover patterns blurred in large datasets because women reach that point at different ages. The paper reports that dysregulation in some measures began more than a decade earlier and that the aggregate shifts sharpened at the final period. It does not say every symptom emerges in one day.[2]
Large sample cannot set an individual timetable
Australian menopause specialists interviewed by ABC, who were not involved in the research, challenged the physiological-cliff description. They warned that presenting an aggregate break as a change experienced at the same moment and intensity by every woman can mislead. The analysis realigns laboratory records; it is not a clinical trial that followed each participant with the same measures from before through after her final period.[1]
Some abrupt changes appeared weaker among women using menopausal hormone therapy. The association between treatment status and measured patterns remains observational. Establishing whether therapy prevents these changes requires a separate randomized test. Different health histories and treatment timing can affect comparisons between observational groups. Applying these findings to care would require separate assessment of individual circumstances.[2]
Two datasets carry the pattern independently
The authors compared reconstructed trajectories in two separate populations. The main direction of breaks in endocrine, skeletal, liver, kidney and lipid measures was consistent across them, while no corresponding final-period-anchored step appeared in male records. Those comparisons argue against a pattern confined to one health system’s laboratory data. The method nonetheless estimates a missing transition date in both datasets rather than observing every individual transition directly.[1], [2]
The independent experts reported by ABC distinguish lived symptoms from population averages in blood tests. The study offers a large record base for asking which biological measures change and when. The aggregate curve does not by itself decide when or how to treat someone experiencing symptoms. Its strength is the breadth of measurements; its limit is the gap between those reconstructed measurements and an individual experience.[1]
